The treatment of breast cancer has been improving for the past two decades, along with survival rates.
This is according to Dr Mark Matfield, scientific co-ordinator at the Association for International Cancer Research.
Dr Matfield said that much of the improvement is the result of long-term investment in research possibilities.
His comments follows news from Cancer Research UK, which revealed that a new drug designed to treat patients with advanced breast cancer has been launched in the UK following its approval earlier this year.
The new chemotherapy drug Eribulin, brand name Halaven, is derived from chemicals in marine sponges.
Dr Matfield remarked: "We know this drug can help prolong the lives of women with advanced breast cancer. However, that is only the first thing that has been discovered, because the whole process of clinical drug testing starts out with advanced cancer patients.
"This drug may be even more useful for the treatment of early breast cancer."